Ya Mei Bai Selected Research

Schizophrenia (Dementia Praecox)

1/2018	Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan.
6/2013	Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.
7/2011	Intercorrelations between the Personal and Social Performance Scale, cognitive function, and activities of daily living.
2/2011	Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.
6/2010	Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
6/2009	Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
12/2007	Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.
8/2007	Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ya Mei Bai Research Topics

Disease

8	Schizophrenia (Dementia Praecox) 01/2018 - 08/2007
5	Body Weight (Weight, Body) 01/2018 - 12/2007
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 06/2013 - 12/2007
4	Weight Gain 06/2011 - 07/2006
2	Body Weight Changes 12/2011 - 06/2010
2	Psychotic Disorders (Schizoaffective Disorder) 07/2011 - 01/2011
1	Treatment-Resistant Depressive Disorder 01/2018
1	Major Depressive Disorder (Major Depressive Disorders) 01/2018
1	Hypertriglyceridemia 01/2012
1	Sialorrhea 07/2011
1	Deglutition Disorders (Dysphagia) 07/2011
1	Parkinson Disease (Parkinson's Disease) 07/2011
1	Tremor (Tremors) 07/2011
1	Hypokinesia (Bradykinesia) 07/2011
1	Neurologic Gait Disorders (Gait, Hemiplegic) 07/2011
1	Parkinsonian Disorders (Parkinsonism) 07/2011
1	Hyperglycemia 06/2011
1	Mania (Manias) 11/2009
1	Tardive Dyskinesia 04/2009
1	Hypoadiponectinemia 12/2007
1	Hyperprolactinemia 06/2007

Drug/Important Bio-Agent (IBA)

10	Antipsychotic Agents (Antipsychotics)IBA 01/2018 - 07/2006
7	Clozapine (Clozaril)FDA LinkGeneric 06/2013 - 07/2006
4	Risperidone (Risperdal Consta)FDA LinkGeneric 06/2013 - 06/2007
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2007
3	Olanzapine (Zyprexa)FDA Link 06/2013 - 06/2009
2	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 06/2011
2	LipidsIBA 01/2018 - 06/2009
2	antiarrhythmic peptide (AAP)IBA 12/2011 - 06/2010
2	AdiponectinIBA 06/2009 - 12/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	Paliperidone Palmitate FDA Link 01/2018
1	microsomal triglyceride transfer proteinIBA 06/2013
1	O(4)-methylthymidine triphosphateIBA 06/2013
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 12/2011
1	Aripiprazole (Abilify)FDA Link 07/2011
1	Quetiapine Fumarate (Seroquel)FDA Link 07/2011
1	Pharmaceutical PreparationsIBA 07/2011
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 07/2011
1	Blood Glucose (Blood Sugar)IBA 06/2011
1	5-HT2C Serotonin ReceptorIBA 02/2011
1	Serotonin (5 Hydroxytryptamine)IBA 02/2011
1	TabletsIBA 01/2011
1	Dopamine Receptors (Dopamine Receptor)IBA 06/2010
1	Tamoxifen FDA LinkGeneric 11/2009
1	Hormones (Hormone)IBA 06/2009
1	HDL CholesterolIBA 12/2007
1	Insulin (Novolin)FDA Link 12/2007
1	Triglycerides (Triacylglycerol)IBA 12/2007

Therapy/Procedure

1	Therapeutics 01/2018
1	Activities of Daily Living (ADL) 07/2011
1	Duration of Therapy 06/2011